Runben Biotechnology Co Ltd Ordinary Shares - Class A
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd. operates as a subsidiary of Guangzhou Zhuofan Investment Holding Co., L… Read more
Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) - Total Liabilities
Latest total liabilities as of September 2025: CN¥134.06 Million CNY
Based on the latest financial reports, Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) has total liabilities worth CN¥134.06 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Total Liabilities Trend (2019–2024)
This chart illustrates how Runben Biotechnology Co Ltd Ordinary Shares - Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Runben Biotechnology Co Ltd Ordinary Shares - Class A Competitors by Total Liabilities
The table below lists competitors of Runben Biotechnology Co Ltd Ordinary Shares - Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NHN KCP Corp
KQ:060250
|
Korea | ₩320.33 Billion |
|
NIIT LEARNING SYSTEMS LTD
NSE:NIITMTS
|
India | ₹12.34 Billion |
|
Circassia Group Plc
OTCGREY:CSSPF
|
USA | $6.60 Million |
|
Manorama Industries Limited
NSE:MANORAMA
|
India | ₹4.61 Billion |
|
338840
KQ:338840
|
Korea | ₩3.17 Billion |
|
Tristel PLC
PINK:TSNLF
|
USA | $11.88 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
USA | $270.47 Million |
|
389650
KQ:389650
|
Korea | ₩11.84 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Runben Biotechnology Co Ltd Ordinary Shares - Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Runben Biotechnology Co Ltd Ordinary Shares - Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Runben Biotechnology Co Ltd Ordinary Shares - Class A (2019–2024)
The table below shows the annual total liabilities of Runben Biotechnology Co Ltd Ordinary Shares - Class A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥138.88 Million | +42.28% |
| 2023-12-31 | CN¥97.61 Million | -5.08% |
| 2022-12-31 | CN¥102.83 Million | +21.42% |
| 2021-12-31 | CN¥84.69 Million | +221.67% |
| 2020-12-31 | CN¥26.33 Million | -2.74% |
| 2019-12-31 | CN¥27.07 Million | -- |